Cox-2 in non-small cell lung cancer: A meta-analysis

Clinica Chimica Acta

Volumn 419, Issue , 2013, Pages 26-32

  Jiang, Hao ^a   Wang, Jing ^b   Zhao, Wei ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

Cyclooxygenase 2; Hazard ratio; Meta analysis; Non small cell lung cancer; NSCLC; Prognosis

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA;

CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HAZARD RATIO; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MEDICAL INFORMATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 84874376667     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.01.012     Document Type: Review

References (52)

1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
2. Jett J.R., Scott W.J., Rivera M.P., Sause W.T. American College of Chest Physicians. Guidelines on treatment of stage IIIB nonsmall cell lung cancer. Chest 2003, 123:221S-225S.
3. Hida T., Yatabe Y., Achiwa H., et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998, 58:3761-3764.
4. Hwang D., Scollard D., Byrne J., Levine E. Expression cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998, 90:455-460.
5. Ogino S., Kirkner G.J., Nosho K., et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008, 14:8221-8227.
6. Dannenberg A.J., Altorki N.K., Boyle J.O., et al. Cyclooxygenase-2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001, 2:544-551.
7. Araki K., Hashimoto K., Ardyanto T.D., et al. Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas. Lung Cancer 2004, 45:161-169.
8. Kim H.S., Youm H.R., Lee J.S., Min K.W., Chung J.H., Park C.S. Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 2003, 42:163-170.
9. Yuan A., Yu C.J., Shun C.T., et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 2005, 115:545-555.
10. Yamaguchi N.H., Lichtenfels A.J., Demarchi L.M., et al. COX-2, MMP-9, and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. A study of 117 patients from Brazil. Am J Clin Pathol 2004, 121:78-86.
11. Mascaux C., Martin B., Paesmans M., et al. Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer 2006, 95:139-145.
12. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
13. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985, 27:335-371.
14. Egger M., Smith G.D., Schneider M., Minder C. Bias in meta analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
15. Achiwa H., Yatabe Y., Hida T., et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999, 5:1001-1005.
16. Brabender J., Park J., Metzger R., et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002, 235:440-443.
17. Khuri F.R., Wu H., Lee J.J., et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001, 7:861-867.
18. Laga A.C., Zander D.S., Cagle P.T. Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer. Arch Pathol Lab Med 2005, 129:1113-1117.
19. Lu C., Soria J.C., Tang X., et al. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 2004, 22:4575-4583.
20. Richardson C.M., Richardson D., Swinson D.E., Swain W.A., Cox G., O'Byrne K.J. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Lung Cancer 2005, 48:47-57.
21. Byun J.H., Lee M.A., Roh S.Y., Shim B.Y., Hong S.H., Ko Y.H. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Jpn J Clin Oncol 2006, 36:263-268.
22. Edelman M.J., Watson D., Wang X.F., Morrison C., Kratzke R.A., Jewell S. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib_chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008, 26:848-855.
23. Kim G.Y., Lim S.J., Kim Y.W. Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas. Mod Pathol 2011, 24:1336-1347.
24. Lee J.M., Mao J.T., Krysan K., Dubinett S.M. Significance of Cyclooxygenase-2 in prognosis, target therapy and chemoprevention of NSCLC. Future Oncol 2007, 3:149-153.
25. Lim B.J., Jung S.S., Choi S.Y., Lee C.S. Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance. Mol Med Rep 2010, 3:43-49.
26. Tsubochi H., Sato N., Hiyama M., et al. Combined analysis of cyclooxyenase-2 expression with p53 and Ki-67 in non small cell lung cancer. Ann Thorac Surg 2006, 82:1198-1204.
27. Van Dyke A.L., Cote M.L., Prysak G.M., et al. COX-2/EGFR expression and survival among women with adenocarcinoma of the lung. Carcinogenesis 2008, 29:1781-1787.
28. Wu Y.C., Su L.J., Wang H.W., et al. Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer. J Thorac Oncol 2010, 5:1167-1174.
29. Wu X.H., Cheng Q., Kai Y. Correlations of hypoxia-inducible factor-1α/hypoxia-inducible factor-2α expression with angiogenesis factors expression and prognosis in non-small cell lung cancer. Chin Med J 2011, 124:11-18.
30. Shimizu K., Hirami Y., Saisho S., et al. Maximal standardized uptake value on FDG-PET is correlated with cyclooxygenase-2 expression in patients with lung adenocarcinoma. Ann Thorac Surg 2012, 93:398-404.
31. Fidler M.J., Argiris A., Patel J.D. The potential predictive value of cyclooxygenase-2 hemorrhage in advanced non-small cell lung cancer expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res 2008, 14:2088-2094.
32. Kim S.J., Rabbani Z.N., Dong F., et al. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med Oncol 2010, 27:91-97.
33. Groen H.J., Sietsma H., Vincent A., et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol 2011, 29:4320-4326.
34. Cathcart M.C., Gately K., Cummins R., Kay E., Byrne K.J., Pidgeon G.P. Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Mol Cancer 2011, 10. 10.1186/1476-4598-10-25.
35. Edelman M.J., Hodgson L., Wang X.F., et al. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. J Thorac Oncol 2011, 6:1902-1906.
36. Brattstrom D., Wester K., Bergqvist M., et al. HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell Lung cancer. Acta Oncol 2005, 43:80-86.
37. Hosomi Y., Yokose T., Hirose Y., et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000, 30:73-81.
38. Marrogi A.J., Travis W.D., Welsh J.A., et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000, 6:4739-4744.
39. Li F., Liu Y.M., Chen H.J., et al. EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features. J Exp Clin Cancer Res 2011, 30:27. 10.1186/1756-9966-30-27.
40. Ab' Saber A.M., Massoni Neto L.M., Bianchi C.P., et al. Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas. Ann Thorac Surg 2004, 77:1883-1890.
41. Strazisar M., Rott T., Glava Damjan K-RAS and P53 mutations in association with COX-2 and hTERT expression and clinico-pathological status of NSCLC patients. Dis Markers 2008, 25:97-106.
42. Surowiak P., Pawelczyk K., Maciejczyk A., et al. Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer. Anticancer Res 2008, 28:2967-2974.
43. Timotheadou E., Skarlos D.V., Samantas E., et al. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients. Anticancer Res 2007, 27:4481-4490.
44. Turk H.M., Camci C., Sevinc A., Bukyukberber S., Sari I., Adli M. Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer. Asian Pac J Cancer Prev 2012, 13:315-318.
45. Cha Y.I., DuBois R.N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007, 58:239-252.
46. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60:1306-1311.
47. Liu X.H., Yao S., Kirschenbaum A., Levine A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998, 58:4245-4249.
48. Martin Sanz P., Hortelano S., Bosca L., Casado M. Cyclooxygenase 2: understanding the pathophysiological role through genetically altered mouse models. Front Biosci 2006, 11:2876-2888.
49. Liu C.H., Chang S.H., Narko K., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001, 276:18563-18569.
50. Krzystyniak K.L. Current strategies for anticancer chemoprevention and chemoprotection. Acta Pol Pharm 2002, 59:473-478.
51. Guo X.F., Chen Y.B., Xu Z.H., Qian Y.Y., Yu X.F. Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer. Acta Biochim Biophys Sin 2009, 41:217-222.
52. Denkert C., Köbel M., Pest S., et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol March 2002, 160:893-903.